Potential functional and survival benefit of double over single lung transplantation for selected patients with idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis (IPF) is a frequent indication for lung transplantation (LTX) with pulmonary hypertension (PH) negatively affecting outcome. The optimal procedure type remains a debated topic. The aim of this study was to evaluate the impact of pretransplant PH in IPF patients. Single LTX (SLTX, n = 46) was the standard procedure type. Double LTX (DLTX, n = 30) was only performed in cases of relevant PH or additional suppurative lung disease. There was no significant difference for pretransplant clinical parameters. Preoperative mean pulmonary arterial pressure was significantly higher in DLTX recipients (22.7 +/- 0.8 mmHg vs. 35.9 +/- 1.8 mmHg, P < 0.001). After transplantation, 6-min-walk distance and BEST-FEV(1) were significantly higher for DLTX patients (6-MWD: 410 +/- 25 m vs. 498 +/- 23 m, P = 0.02; BEST-FEV(1): 71.2 +/- 3.0 (% pred) vs. 86.2 +/- 4.2 (% pred), P = 0.004). Double LTX recipients demonstrated a significantly better 1-year-, overall- and Bronchiolitis obliterans Syndrome (BOS)-free survival (P < 0.05). Cox regression analysis confirmed SLTX to be a significant predictor for death and BOS. Single LTX offers acceptable survival rates for IPF patients. Double LTX provides a significant benefit in selected recipients. Our data warrant further trials of SLTX versus DLTX stratifying for potential confounders including PH.
Neurohr
Claus
C
Division of Pulmonary Diseases, Department of Internal Medicine I, Klinikum Grosshadern, Ludwig-Maximilians University, Munich, Germany. claus.neurohr@med.uni-muenchen.de
Huppmann
Patrick
P
Thum
Dolores
D
Leuschner
Werner
W
von Wulffen
Werner
W
Meis
Tobias
T
Leuchte
Hanno
H
Baumgartner
Rainer
R
Zimmermann
Gregor
G
Hatz
Rudolf
R
Czerner
Stephan
S
Frey
Lorenz
L
Ueberfuhr
Peter
P
Bittmann
Iris
I
Behr
Juergen
J
D018572:Disease-Free Survival; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D005541:Forced Expiratory Volume / Q000502:physiology; D005858:Germany / Q000453:epidemiology; D006085:Graft Survival / Q000502:physiology*; D006801:Humans; D054990:Idiopathic Pulmonary Fibrosis / Q000401:mortality / Q000503:physiopathology / Q000601:surgery*; D016040:Lung Transplantation / Q000379:methods* / Q000401:mortality; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome